FDA DEVICE FACTS
FoundationOne CDx
Foundation Medicine, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
FoundationOne CDx™ (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels) and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. The F1CDx test is a single-site assay performed at Foundation Medicine, Inc.
Table 1. Companion diagnostic indications Indication Biomarker Therapy Non-small cell lung cancer (NSCLC) EGFR exon 19 deletions and EGFR exon 21 L858R alterations Gilotrif® (afatinib), Iressa® (gefitinib), or Tarceva® (erlotinib) EGFR exon 20 T790M alterations
Tagrisso® (osimertinib) ALK rearrangements Alecensa® (alectinib), Xalkori® (crizotinib), or Zykadia® (ceritinib) BRAF V600E Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) Melanoma BRAF V600E
Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib)
BRAF V600E and V600K
Mekinist® (trametinib) or Cotellic® (cobimetinib) in combination with Zelboraf® (vemurafenib) Breast cancer
ERBB2 (HER2) amplification
Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab) Colorectal cancer KRAS wild-type (absence of mutations in codons 12 and 13) Erbitux® (cetuximab) KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) Vectibix® (panitumumab) Ovarian cancer BRCA1/2 alterations Rubraca® (rucaparib)
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。